Digest Network Come funziona
Network
/
Società
Cy
Non verificato

Cyllene Therapeutics

Di cosa scriviamo

Annunci EconomiciFinanzaMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

5 comunicati stampa

Guarda tutti i comunicati
17/09/2026
Pubblicità/Marketing/Media/Comunicazione
Medicina Salute Benessere
Cyllene Therapeutics Appoints Seasoned Biotech Executive Dr Marc Grasso as Chief Financial Officer
Fonte
Cyllene Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
14/09/2026
Pubblicità/Marketing/Media/Comunicazione
Medicina Salute Benessere
Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)
Fonte
Cyllene Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
22/07/2026
Annunci Economici
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Fonte
Cyllene Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
06/07/2026
Finanza
Cyllene Therapeutics (anciennement EG427) lève 33 millions d’euros lors d’une Série C pour accélérer le développement clinique d’EG110A et l’expansion de son pipeline
Fonte
Cyllene Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0
06/07/2026
Finanza
Cyllene Therapeutics (formerly known as EG 427) Raises €33 Million Series C Financing to Advance Clinical Development of EG110A and Pipeline Expansion
Fonte
Cyllene Therapeutics
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0